| HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms RC Hartkoorn, W San Kwan, V Shallcross, A Chaikan, N Liptrott, D Egan, ... Pharmacogenetics and genomics 20 (2), 112-120, 2010 | 217 | 2010 |
| Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics U Arshad, H Pertinez, H Box, L Tatham, RKR Rajoli, P Curley, M Neary, ... Clinical Pharmacology & Therapeutics 108 (4), 775-790, 2020 | 158 | 2020 |
| Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction SP Pushpakom, NJ Liptrott, S Rodríguez-Nóvoa, P Labarga, V Soriano, ... Journal of Infectious Diseases 204 (1), 145-153, 2011 | 144 | 2011 |
| The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC NJ Liptrott, M Penny, PG Bray, J Sathish, SH Khoo, DJ Back, A Owen British journal of pharmacology 156 (3), 497-508, 2009 | 100 | 2009 |
| Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro–in vivo correlation TO McDonald, M Giardiello, P Martin, M Siccardi, NJ Liptrott, D Smith, ... Advanced healthcare materials 3 (3), 400-411, 2014 | 95 | 2014 |
| Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir DM Moss, WS Kwan, NJ Liptrott, DL Smith, M Siccardi, SH Khoo, DJ Back, ... Antimicrobial agents and chemotherapy 55 (2), 879-887, 2011 | 71 | 2011 |
| Immunotoxicity considerations for next generation cancer nanomedicines G Hannon, J Lysaght, NJ Liptrott, A Prina‐Mello Advanced Science 6 (19), 1900133, 2019 | 68 | 2019 |
| Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis RKR Rajoli, H Pertinez, U Arshad, H Box, L Tatham, P Curley, M Neary, ... British Journal of Clinical Pharmacology 87 (4), 2078-2088, 2021 | 65 | 2021 |
| Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS NJ Liptrott, S Pushpakom, C Wyen, G Fätkenheuer, C Hoffmann, S Mauss, ... Pharmacogenetics and genomics 22 (1), 10-19, 2012 | 60* | 2012 |
| Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies M Giardiello, NJ Liptrott, TO McDonald, D Moss, M Siccardi, P Martin, ... Nature communications 7 (1), 13184, 2016 | 57 | 2016 |
| Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance–based detection in vivo J Sharkey, PJS Lewis, M Barrow, SM Alwahsh, J Noble, E Livingstone, ... Cytotherapy 19 (4), 555-569, 2017 | 56 | 2017 |
| Bridging communities in the field of nanomedicine B Halamoda-Kenzaoui, S Baconnier, T Bastogne, D Bazile, P Boisseau, ... Regulatory Toxicology and Pharmacology 106, 187-196, 2019 | 43 | 2019 |
| Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation P Curley, RKR Rajoli, DM Moss, NJ Liptrott, S Letendre, A Owen, ... Antimicrobial agents and chemotherapy 61 (1), 10.1128/aac. 01841-16, 2017 | 41 | 2017 |
| Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation B Halamoda-Kenzaoui, RJ Vandebriel, A Howarth, M Siccardi, ... Journal of Controlled Release 336, 192-206, 2021 | 40 | 2021 |
| Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro DM Moss, NJ Liptrott, P Curley, M Siccardi, DJ Back, A Owen Antimicrobial agents and chemotherapy 57 (11), 5612-5618, 2013 | 40 | 2013 |
| Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies P Urbán, NJ Liptrott, S Bremer Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 11 (3 …, 2019 | 39 | 2019 |
| Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines M Rösslein, NJ Liptrott, A Owen, P Boisseau, P Wick, IK Herrmann Nanotoxicology 11 (2), 147-149, 2017 | 39 | 2017 |
| Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches CAW David, A Owen, NJ Liptrott Nanomedicine 11 (11), 1447-1464, 2016 | 35 | 2016 |
| Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals A Jackson, V Watson, D Back, S Khoo, N Liptrott, D Egan, K Gedela, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 58 (5), 450-457, 2011 | 35 | 2011 |
| Induction of cytokines by nucleic acid nanoparticles (NANPs) depends on the type of delivery carrier YI Avila, M Chandler, E Cedrone, HS Newton, M Richardson, J Xu, ... Molecules 26 (3), 652, 2021 | 33 | 2021 |
Andrew OwenUniversity of Liverpool在 liv.ac.uk 的电子邮件经过验证
